N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Sponsor: Novo Nordisk A/S • ClinicalTrials.gov ID: NCT07415954

Registry updated: 2026-09-11
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

Interventions

  • NNC0662-0419 (Drug)
    NNC0662-0419 will be administered subcutaneously.
  • Semaglutide (Drug)
    Semaglutide will be administered subcutaneously.
  • Placebo (Drug)
    Placebo will be administered subcutaneously.

Eligibility criteria

Inclusion criteria * Male or female (sex at birth). * Age 18-75 years (both inclusive) at the time of signing the informed consent. * Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening. * Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline). Exclusion criteria * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.

Conditions

Diabetes Mellitus, Type 2

Locations

  • First Valley Medical Group — Lancaster, California, United States
  • Torrance Clinical Research Institute, Inc. — Lomita, California, United States
  • Ark Clinical Research — Long Beach, California, United States
  • Pacific Clinical Studies — Los Alamitos, California, United States
  • Wetlin Research Associates, Inc. — San Diego, California, United States
  • Diablo Clinical Research, Inc. — Walnut Creek, California, United States
  • Encore Medical Research LLC — Hollywood, Florida, United States
  • Bioclinical Research Alliance — Miami, Florida, United States
  • South Broward Research LLC — Miramar, Florida, United States
  • West Orange Endocrinology — Ocoee, Florida, United States
  • Encore Medical Research of Weston — Weston, Florida, United States
  • Elite Clinical Trials — Blackfoot, Idaho, United States
  • Cedar-Crosse Research Center — Chicago, Illinois, United States
  • Brigham & Women's Hospital — Boston, Massachusetts, United States
  • Headlands Research — Springfield, Missouri, United States
  • PharmQuest — Greensboro, North Carolina, United States
  • Piedmont Healthcare Statesville — Statesville, North Carolina, United States
  • Providence Center for Clinical Research — Dayton, Ohio, United States
  • CNS Healthcare — Memphis, Tennessee, United States
  • University of Texas Southwestern Medical Center — Dallas, Texas, United States
  • JCCT- Juno NW Houston — Houston, Texas, United States
  • Consano Clinical Research, LLC — Shavano Park, Texas, United States
  • Frontier Clinical Research - Kingwood — Kingwood, West Virginia, United States
  • Opca bolnica Karlovac — Karlovac, Croatia
  • Poliklinika SLAVONIJA OSIJEK — Osijek, Croatia
  • Opca bolnica Varazdin_Endocrinology — Varaždin, Croatia
  • Poliklinika Solmed — Zagreb, Croatia
  • Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ — Szeged, Csongrád-Csanád, Hungary
  • Debreceni Egyetem — Debrecen, Hajdú-Bihar, Hungary
  • Debreceni Egyetem — Debrecen, Hungary
  • Akaicho Clinic_Internal medicine — Chiba-shi, Chiba, Japan
  • Naka Kinen Clinic_Internal medicine — Ibaraki, Japan
  • Soka Sugiura Internal Medicine Clinic — Soka-shi, Saitama, Japan
  • Tokyo-Eki Center-building Clinic_Internal Medicine — Tokyo, Japan
  • ToCROM Clinic_Internal Medicine — Tokyo, Japan
  • "Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik — Bialystok, Podlaskie Voivodeship, Poland
  • Terpa Sp. z o.o. Sp. k. — Lublin, Poland
  • Formed 2 Sp. z o.o. — Oświęcim, Poland
  • PANSTWOWY INSTYTUT MEDYCZNY MSWiA — Warsaw, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko — Zabrze, Poland
  • Casa De Saúde De Santa Filomena S.A._Unidade de Ensaios Clínicos — Coimbra, Portugal
  • Cardiolima Centro Diagnostico Cardio-Pulmonar De Ponte De Lima Lda — Ponte de Lima, Portugal
  • Hospital Trofa Saude Senhor do Bonfim S.A_Unidade de Ensaios Clínicos — Vila do Conde, Portugal
  • Hospital da Luz Arrábida, S.A_Serviço de Endocrinologia — Vila Nova de Gaia, Portugal
  • DIADA, s.r.o. — Bardejov, Slovakia
  • Metabol KLINIK s.r.o. — Bratislava, Slovakia
  • Diacrin s. r. o. — Bratislava, Slovakia
  • SIN AZUCAR s.r.o. — Malacky, Slovakia
  • Korea University Ansan Hospital_Endocrinology — Ansan-si, Gyeonggi-do, South Korea
  • Pusan National University Yangsan Hospital_Family Medicine — Yangsan, Gyeongsangnam-do, South Korea
  • Nowon Eulji Medical Center, Eulji University_Endocrinology — Seoul, South Korea
  • Kangbuk Samsung Hospital_Endocrinology — Seoul, South Korea
  • ABS La Roca CAP Vicenç_Endocrino — La Roca Del Vallés, Barcelona, Spain
  • Centro de Salud A Estrada — A Estrada, Spain
  • Equip D´Atencio Primaria Barcelona Sardenya — Barcelona, Spain
  • Hospital Vithas Sevilla — Castilleja de la Cuesta, Spain
  • Clínica Bofill — Girona, Spain
  • Centro de Saúde Concepción Arenal — Santiago de Compostela, Spain
  • Ramathibodi Hospital — Bangkok, Thailand
  • Siriraj Hospital — Bangkok, Thailand
  • Maharaj Nakorn Chiang Mai — Chiang Mai, Thailand
  • Srinagarind Hospital — Khon Kaen, Thailand
  • Maharat Nakhon Ratchasima Hospital — Nakhon Ratchasima, Thailand
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record